Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- GNLX
- Price
- 2.46
- Stock movement up
- +0.12 (5.13%)
- Company name
- Genelux Corporation Common Stock
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 84.96M
- Ent value
- 86.04M
- Price/Sales
- 57.72
- Price/Book
- 2.57
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -43.45%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-11
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
GNLX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 57.72 |
| Price to Book | 2.57 |
| EV to Sales | 58.45 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 34.54M |
| EPS (TTM) | -0.80 |
| FCF per share (TTM) | -0.71 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 1.47M |
| Gross profit (TTM) | 819.00K |
| Operating income (TTM) | -28.95M |
| Net income (TTM) | -27.66M |
| EPS (TTM) | -0.80 |
| EPS (1y forward) | -1.22 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 55.64% |
| Operating margin (TTM) | -1966.64% |
| Profit margin (TTM) | -1879.08% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 6.10M |
| Net receivables | 0.00 |
| Total current assets | 35.97M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 6.83M |
| Total assets | 40.27M |
| Accounts payable | 4.45M |
| Short/Current long term debt | 2.04M |
| Total current liabilities | 5.55M |
| Total liabilities | 7.18M |
| Shareholder's equity | 33.09M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -23.84M |
| Capital expenditures (TTM) | 528.00K |
| Free cash flow (TTM) | -24.36M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -83.59% |
| Return on Assets | -68.69% |
| Return on Invested Capital | -82.55% |
| Cash Return on Invested Capital | -72.72% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.35 |
| Daily high | 2.48 |
| Daily low | 2.21 |
| Daily Volume | 184K |
| All-time high | 38.00 |
| 1y analyst estimate | 18.40 |
| Beta | - |
| EPS (TTM) | -0.80 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| GNLX | S&P500 | |
| Current price drop from All-time high | -93.53% | -12.89% |
| Highest price drop | -95.74% | -56.47% |
| Date of highest drop | 5 Aug 2024 | 9 Mar 2009 |
| Avg drop from high | -63.97% | -11.07% |
| Avg time to new high | 25 days | 12 days |
| Max time to new high | 455 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
84.96M
Marketcap category
Small-cap
Description
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Employees
24
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page